1. An immunologically relevant rodent model demonstrates safety of therapy using a tumour‐specific IgE. Issue 12 (8th October 2018) Authors: Josephs, D. H.; Nakamura, M.; Bax, H. J.; Dodev, T. S.; Muirhead, G.; Saul, L.; Karagiannis, P.; Ilieva, K. M.; Crescioli, S.; Gazinska, P.; Woodman, N.; Lombardelli, C.; Kareemaghay, S.; Selkirk, C.; Lentfer, H.; Barton, C.; Canevari, S.; Figini, M.; Downes, N.; Dombrowicz, D. Journal: Allergy Issue: Volume 73:Issue 12(2018) Page Start: 2328 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PS-04-004 The Pharmacological Profile of IX-01, A Selective Oxytocin Receptor Antagonist being Developed to Treat Men with Premature Ejaculation. (1st April 2017) Authors: Osterloh, I.; Muirhead, G.; Gibson, K.; van den Berg, F.; Wayman, C. Journal: Journal of sexual medicine Issue: Volume 14(2017)Supplement 4a Page Start: e117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SP-0258: Potentiation of anti-tumor immune effects by PARP Inhibitors. (November 2020) Authors: Chabanon, R.; Muirhead, G.; Krastev, D.; Adam, J.; Garrido, M.; Morel, D.; Dorvault, N.; Pettitt, S.; Tutt, A.N.J.; Marabelle, A.; Soria, J.C.; Lord, C.J.; Postel-Vinay, S. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗